Aortic Valve Replacement in Women
JACC: Cardiovascular Interventions · 2025
DOI: 10.1016/j.jcin.2025.03.036 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Helene Eltchaninoff und 17 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rouen Normandie, Inserm U 1096, CHU Rouen, Department of Cardiology, Rouen, France. Electronic address: helene.eltchaninoff@chu-rouen.fr. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Aortic Valve, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In women with severe aortic stenosis, there are limited data regarding outcome differences following transcatheter (TAVR) vs surgical aortic valve replacement (SAVR). OBJECTIVES: The authors sought to examine outcomes of TAVR vs SAVR in a patient-level pooled analysis of women in the RHEIA and PARTNER 3 trials. METHODS: Patients in both trials were randomly allocated to a balloon-expandable SAPIEN 3/Ultra valve or to surgical bioprostheses. Individual patient data of female participants in the 2 trials were pooled. The primary endpoint was all-cause mortality, all stroke, or rehospitalization at 1 year. RESULTS: A total of 376 women were randomized to TAVR and 336 to SAVR. The mean age was ∼73 years, and the mean Society of Thoracic Surgeons (STS) score was 2.1%. Kaplan-Meier estimates of event rates at 1 year with TAVR vs SAVR were 8.5% vs 16.8% for the composite of all-cause mortality, all stroke, or rehospitalization (absolute difference -8.2%; 95% CI: -13.1% to -3.3%; P < 0.001), 1.1% vs 2.1% (P = 0.27) for all-cause mortality, 2.7% vs 3.9% (P = 0.35) for all stroke, and 5.4% vs 11.9% (P = 0.002) for rehospitalization. The composite endpoint of all-cause death or stroke was similar between the 2 treatment groups: 3.5% vs 5.4% (absolute difference -1.9%; 95% CI: -5.0% to 1.1%; P = 0.21). CONCLUSIONS: Among women with symptomatic severe aortic stenosis, TAVR led to a reduction in the rate of the combined endpoint of all-cause mortality, stroke, or rehospitalization at 1-year follow-up, largely due to a significant reduction in the rate of rehospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Univ Rouen Normandie, Inserm U 1096, CHU Rouen, Department of Cardiology, Rouen, France. Electronic address: helene.eltchaninoff@chu-rouen.fr.
- Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
- Baylor Scott & White Health, Plano, Texas, USA.
- Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
- Piedmont Heart Institute, Atlanta, Georgia, USA.
- Leiden University Medical Center, Leiden, the Netherlands.
Zitieren
APA
Eltchaninoff, H., Windecker, S., Mack, M. J., Pibarot, P., Thourani, V. H., Bax, J. J., Cohen, D. J., Bonaros, N., Makkar, R., Bleiziffer, S., Szeto, W. Y., Berthoumieu, P., Hahn, R. T., Hovorka, T., Mareš, J., Taylor, J., Tchetche, D., & Leon, M. B. (2025). Aortic Valve Replacement in Women. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.03.036
Vancouver
Eltchaninoff H, Windecker S, Mack MJ, Pibarot P, Thourani VH, Bax JJ, et al. Aortic Valve Replacement in Women. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.03.036
BibTeX
@article{Eltchaninoff2025,
author = {Eltchaninoff, Helene and Windecker, Stephan and Mack, Michael J and Pibarot, Philippe and Thourani, Vinod H and Bax, Jeroen J and Cohen, David J and Bonaros, Nikolaos and Makkar, Raj and Bleiziffer, Sabine and Szeto, Wilson Y and Berthoumieu, Pierre and Hahn, Rebecca T and Hovorka, Tomas and Mareš, Jan and Taylor, Jennifer and Tchetche, Didier and Leon, Martin B},
title = {Aortic Valve Replacement in Women},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
doi = {10.1016/j.jcin.2025.03.036}
}
EUVIMED